Novel amino substituted tetracyclic imidazo[4,5-b]pyridine derivatives: Design, synthesis, antiproliferative activity and DNA/RNA binding study. 2021

Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
Pliva d.o.o., odjel TAPI I&R, Unapređenje tehnoloških procesa i Podrška proizvodnji, Croatia.

A novel series of tetracyclic imidazo[4,5-b]pyridine derivatives was designed and synthesized as potential antiproliferative agents. Their antiproliferative activity against human cancer cells was influenced by the introduction of chosen amino side chains on the different positions on the tetracyclic skeleton and particularly, by the position of N atom in the pyridine nuclei. Thus, the majority of compounds showed improved activity in comparison to standard drug etoposide. Several compounds showed pronounced cytostatic effect in the submicromolar range, especially on HCT116 and MCF-7 cancer cells. The obtained results have confirmed the significant impact of the position of N nitrogen in the pyridine ring on the enhancement of antiproliferative activity, especially for derivatives bearing amino side chains on position 2. Thus, regioisomers 6, 7 and 9 showed noticeable enhancement of activity in comparison to their counterparts 10, 11 and 13 with IC50 values in a nanomolar range of concentration (0.3-0.9 μM). Interactions with DNA (including G-quadruplex structure) and RNA were influenced by the position of amino side chains on the tetracyclic core of imidazo[4,5-b]pyridine derivatives and the ligand charge. Moderate to high binding affinities (logKs = 5-7) obtained for selected imidazo[4,5-b]pyridine derivatives suggest that DNA/RNA are potential cell targets.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA

Related Publications

Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
July 2011, European journal of medicinal chemistry,
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
January 2011, Acta poloniae pharmaceutica,
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
January 1982, Polish journal of pharmacology and pharmacy,
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
January 2020, Nucleosides, nucleotides & nucleic acids,
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
September 1993, Farmaco (Societa chimica italiana : 1989),
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
August 2023, Molecular diversity,
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
March 2017, Molecules (Basel, Switzerland),
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
September 1991, Archiv der Pharmazie,
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
December 1998, Anti-cancer drug design,
Borka Lončar, and Nataša Perin, and Marija Mioč, and Ida Boček, and Lea Grgić, and Marijeta Kralj, and Sanja Tomić, and Marijana Radić Stojković, and Marijana Hranjec
January 2015, Acta poloniae pharmaceutica,
Copied contents to your clipboard!